Clinical Evaluation of FOXO1 as a Tumor Suppressor in Prostate Cancer

CONCLUSIONS: In summary, our study suggests that FOXO1 may be one of the prognostic factors that describe the risk of PCa for BCR. These results suggest that FOXO1 may be a therapeutic target for PCa.PMID:34552661 | PMC:PMC8452405 | DOI:10.1155/2021/8773423

Source: Computational and Mathematical Methods in Medicine - September 23, 2021 Category: Statistics Authors: Ning Yang Jiawen Wu Tiancheng Zhang Fan Yang Jinyan Shao Chang He Liang Qin Source Type: research